Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31431111 | 1.00 | DTYMK (0.57) | DTYMKVCAM1CASP6EIF4EMAPT | |
| SCHEMBL1886794 | 0.87 | VCAM1 (0.58) | DTYMKVCAM1CASP6EIF4EMAPT | |
| SCHEMBL16959331 | 0.83 | VCAM1 (0.54) | DTYMKVCAM1MAPTMEN1KMT2A | |
| SCHEMBL15988993 | 0.80 | DTYMK (0.53) | DTYMKCASP6MEN1KMT2ATSHR | |
| SCHEMBL11727517 | 0.79 | VCAM1 (0.53) | DTYMKVCAM1MAPTMEN1KMT2A | |
| SCHEMBL16958448 | 0.78 | VCAM1 (0.49) | VCAM1MAPTMEN1KMT2AKAT2B | |
| SCHEMBL4477143 | 0.78 | VCAM1 (0.70) | VCAM1CASP6MAPTMEN1KMT2A | |
| SCHEMBL31432469 | 0.77 | VCAM1 (0.59) | VCAM1MAPTKMT2ATSHRKAT2B | |
| SCHEMBL1142893 | 0.77 | VCAM1 (0.59) | VCAM1MAPTKMT2ATSHRKAT2B | |
| SCHEMBL16959988 | 0.77 | VCAM1 (0.48) | VCAM1MAPTMEN1KMT2AKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638696-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119320388-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118812532-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-111194215-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-111499615-B | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114007611-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007614-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2021198098-A1 | IMPROVED METHOD OF DETECTING BIOMARKERS IN A BIOLOGICAL SAMPLE | Universität Zürich (CH) | 2021-10-07 | — | — | WO | disclosed |
| CN-111499615-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | DTYMK 1726/4885VCAM1 2957/4885CASP6 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.